Cached score snapshot

US.DGX · Quest Diagnostics

110分制 49.9/110;5D動能v2 5/50;排序分 54.9/160

Ranking score 54.9/160
Main score 49.9/110
5D momentum v2 5/50
Rank #279
Setup grade F 23.4

Score breakdown

避免

Medium twelvedata

Score and price trend

F 23.4 Low sample confidence

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 04-23 07-24 08-06 08-19 08-31 $181.63$214.95$248.27 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 2.819 · anchors 120 +1.05% -1.09% / +3.39% 61% 2.6% Actual +9.75% · vs median +8.70% · inside 25-75 band
30D observation +6.95% +1.36% / +12.94% 79.8% 9.2% Actual outcome pending · 1 / 30 bars observed
Historical projection 10D n=160 +1.18% -0.55% / +3.42% 66.9% 0.6% Actual outcome pending · 1 / 10 bars observed

歷史情境統計基於已存檔相似 setup;圖中投影中位線為統計中位數的線性插值展示,並非價格路徑預測或買賣建議。

2026-04-23 → 2026-08-31 · 322 archived points · 2 Improving turn signal · 4 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 54.9
Display grade 避免
Model version cursor_18_27_news_v2_160
Main score 49.9/110 (避免)
5D momentum v2 5/50 (弱)
Score with momentum v2 54.9/160 (低排序)
Risk level Medium

Audit trace

Full calculation detail

Calculation detail · 8 sections

Market inputs

Bar count 60
ma20 207.936
ma50 200.143
close 207.66
prevClose 210.68
avgVolume20 872799
volumeRatio 0.72
changePercent -1.43

Metrics snapshot

close 207.66
volume 625781
changePercent -1.43

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 49.9/110
Main rating 避免
5D momentum v2 5/50
Score with momentum v2 54.9/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 3.7/5 · 良好

Dimension score 3.7/5
Dimension grade 良好

Sub-items

pbPoints 0.4
pePoints 0.4
epsPoints 0.4
roePoints 0.4
debtPoints 0.4
marginPoints 0
turnoverUsdM 129.9497
volumePoints 0.5
revenuePoints 0.4
dividendPoints 0.3
marketCapPoints 0.5

資金流 — 7.6/20 · 較差

Dimension score 7.6/20
Dimension grade 較差

Sub-items

cmfPoints 1.6
mfiPoints 2.4
obvPoints 0.8
vwapPoints 0.8

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.DGX
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 8/15 · 較差

Dimension score 8/15
Dimension grade 較差

Sub-items

vix

score 1.8

details

source twelvedata+fred
vixClose 18.77

trend

score 0.8

details

qqq

ma20 716.1175
ma50 719.011
name QQQ
close 696.06
points 0.4

spy

ma20 744.7885
ma50 744.5456
name SPY
close 742.09
points 0.4
source twelvedata+fred
atrPct 2.3982
atrPoints 3
cciPoints 2.4
vixPoints 1.8
marketTrendPoints 0.8

催化劑 — 2/20 · 較差

Dimension score 2/20
Dimension grade 較差

Sub-items

catalyst

score 2

details

source finnhub_news_keyword_model
articleCount 4
catalystCount 0
catalystPoints 2

風險管理 — 7.2/10 · 良好

Dimension score 7.2/10
Dimension grade 良好

Sub-items

position

score 1.4

details

atrPct 2.3982
turnoverUsdM 129.9497
liquidityPoints 0.4
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.DGX
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 197.7

strength_details

ma_score 1.5
atr_score 2
rsi_score 1
macd_score 1.5
volume_score 1
market_adjustment 1
risk_reward_ratio 1
stop_loss_percent 4.8
take_profit_price 218.043
target_multiplier 1.6
technical_strength 1.38
take_profit_percent 5
positionPoints 1.4
stopLossPoints 2.4

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 4.7963
diversificationPoints 2

技術信號 — 17.4/30 · 較差

Dimension score 17.4/30
Dimension grade 較差

Sub-items

bbPoints 2.4
adxPoints 3
sarPoints 1.2
vcpPoints 1.5
macdPoints 2.4

vcpPayload

vcp_pass false
vcp_score 1.5
vcp_reason 跌縮量(近10日5日);站上MA50;升放量(近10日2日);Ready=N;Confirm=N

vcp_metrics

up_days 2
vol_ref 893080
down_days 7
vcp_ready false
above_ma50 true
avg_vol_10 831180
avg_vol_20 906120
avg_vol_30 893080
range_pct_10 0.0876
range_pct_20 0.127
range_pct_30 0.127
up_expand_ok true
lookback_used 59
near_20d_high true
contraction_ok false
down_shrink_ok true
up_expand_days 2
breakout_20d_ok false
vol_ratio_10_30 0.9307
dist_to_20d_high 0.0526
down_shrink_days 5
breakout_level_20d 219.2
vcp_breakout_confirm false
contraction_ratio_10_30 0.6902
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction false
kdjAdxPoints 0.7
rsiKdjPoints 2.4
volumeWeight 2
maCrossPoints 1.6
shortRsiPoints 0.8
shortMacdPoints 0.4
volConfirmPoints 0.6
volumePointsTechnical 0.4

情緒分析 — 4/10 · 較差

Dimension score 4/10
Dimension grade 較差

Sub-items

sentiment

score 4

details

source finnhub_news_keyword_model
articleCount 4
negativeHits 0
positiveHits 1
sentimentScoreRaw 0.6

sentimentData

raw {"id":140869905,"url":"https://finnhub.io/api/news?id=7c44cbdf232fd722d46c7c1836b6ff306d3c7cf5dce2f2dc1a99ca8db8c171f0","image":"https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp","source":"ChartMill","related":"DGX","summary":"Quest Diagnostics (DGX) passes the \"Best Dividend\" screen with a sustainable 1.59% yield, low 35% payout ratio, and strong profitability. A solid choice for reliable dividend income and growth.","category":"company","datetime":1783763431,"headline":"Quest Diagnostics (NYSE:DGX) Offers a Secure and Sustainable Dividend with Strong Profitability"}, {"id":140791609,"url":"https://finnhub.io/api/news?id=1163bcc6bf803bb433b2cba9b963d451d95a47f2b2b2a3bc11367cdfed6d0641","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.","category":"company","datetime":1782998102,"headline":"Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?"}, {"id":140734708,"url":"https://finnhub.io/api/news?id=50937ef665125a5be1abc99b47e86bdc8fdd6ca126ac9b39982f3129f5910fda","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Quest Diagnostics (NYSE:DGX) received New York State approval for its Haystack MRD liquid biopsy test, enabling nationwide use for detecting residual or recurrent cancer. The approval follows published research indicating the test’s high sensitivity for minimal residual disease monitoring. Quest Diagnostics also entered a national partnership with Attunio Health to support an AI powered precision psychiatry platform. The partnership is intended to provide scalable laboratory infrastructure...","category":"company","datetime":1782472066,"headline":"Quest Diagnostics (DGX) Wins Nationwide Haystack MRD Access And Expands Into Psychiatry"}, {"id":140725943,"url":"https://finnhub.io/api/news?id=1cda39d77b9b3a359e1e145120f4ed6ac13bbd5d0df48bd64b01106b20f0d053","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Quest Diagnostics gains NYSDOH approval for Haystack MRD, expanding the cancer test to all 50 states and strengthening its oncology reach.","category":"company","datetime":1782397560,"headline":"DGX's Stock Rises on Haystack MRD Test's Approval From NYSDOH"}
raw_source {"id":140940379,"url":"https://finnhub.io/api/news?id=313b6b852fad87101bd818b159b0149e5266b64044b5717f092ff2ac4d12ad63","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"DGX","summary":"A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read here for an analysis.","category":"company","datetime":1784329960,"headline":"Dividend Champion, Contender, And Challenger Highlights: Week Of July 19"}, {"id":140898445,"url":"https://finnhub.io/api/news?id=8cce6b82d94a14e6f1c6129d038c9d068492f45c6095479b1ffc1aafdad7bbfa","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"DGX's Q2 results may reflect growth across physician, hospital and consumer channels as AI tools and advanced diagnostics gain traction.","category":"company","datetime":1784037480,"headline":"Quest Diagnostics to Report Q2 Earnings: Key Customer Channels in Focus"}, {"id":140898225,"url":"https://finnhub.io/api/news?id=b650bd0404d07d15723345af5bfd6859bfe7fe9df9d504ab0885e15a63cbfe95","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"ABT heads into Q2 earnings results with growth expected across Diagnostics, Devices and EPD, while Nutrition remains a drag. Here's what could shape the results.","category":"company","datetime":1784036040,"headline":"Abbott's Q2 Earnings on Deck: How Should You Play the Stock Now?"}, {"id":140886479,"url":"https://finnhub.io/api/news?id=8d5d12187252ef0e8147e50d9c59ae99b9b436fe3ec1128d445997fa97f1f15a","image":"","source":"Benzinga","related":"DGX","summary":"Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $232 to $236.","category":"company","datetime":1783929439,"headline":"Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $236"}, {"id":140869905,"url":"https://finnhub.io/api/news?id=7c44cbdf232fd722d46c7c1836b6ff306d3c7cf5dce2f2dc1a99ca8db8c171f0","image":"https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp","source":"ChartMill","related":"DGX","summary":"Quest Diagnostics (DGX) passes the \"Best Dividend\" screen with a sustainable 1.59% yield, low 35% payout ratio, and strong profitability. A solid choice for reliable dividend income and growth.","category":"company","datetime":1783763431,"headline":"Quest Diagnostics (NYSE:DGX) Offers a Secure and Sustainable Dividend with Strong Profitability"}, {"id":140861842,"url":"https://finnhub.io/api/news?id=dea4a96367e9b1a7e12508fa236e7172cb3413edda8b934757bfbaf6b5228b7b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Nearly one in five workers in the general U.S. workforce (19.1%) tested positive for drug use based on an analysis of hair specimens collected in 2025, an increase of nearly 46% compared to 13.1% in 2021, finds the 2026 Quest Diagnostics Drug Testing Index™. For more information, visit www.QuestDiagnostics.com/DTI.","category":"company","datetime":1783689840,"headline":"One in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use Patterns"}, {"id":140840711,"url":"https://finnhub.io/api/news?id=70f8fddaf6c1d9f28cfb731d0d184f3c03704f72b9b47c49b3aad0e44c40e3a1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced it is integrating its Haystack MRD® ctDNA test and Comprehensive Genomic Profiling services for solid tumor cancers within OncoEMR®, an electronic health record (EHR) from Flatiron Health, via a pilot program with American Oncology Network (AON) and other community oncology providers. Flatiron Health is a leading healthtech company dedicated to expanding the possibilities of point-of-care soluti","category":"company","datetime":1783515120,"headline":"Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI"}, {"id":140821261,"url":"https://finnhub.io/api/news?id=b7403286549b8549769139c3ef0d824ea7877567456fd904a8591fea24374fc6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Zacks highlights PDF Solutions, LifeStance Health and Paychex among stocks and portfolios that outperformed as markets weighed softer jobs data and earnings.","category":"company","datetime":1783343700,"headline":"Beat the Market the Zacks Way: PDF Solutions, LifeStance Health, Paychex in Focus"}, {"id":140795133,"url":"https://finnhub.io/api/news?id=52987caaba1d0a4214a3d3520e4a63c4492060fd2ae8de73a16ba58c60747c14","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"DGX","summary":"A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Explore this week’s dividend updates.","category":"company","datetime":1783015043,"headline":"Dividend Champion, Contender, And Challenger Highlights: Week Of July 5"}, {"id":140791609,"url":"https://finnhub.io/api/news?id=1163bcc6bf803bb433b2cba9b963d451d95a47f2b2b2a3bc11367cdfed6d0641","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.","category":"company","datetime":1782998102,"headline":"Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?"}, {"id":140784902,"url":"https://finnhub.io/api/news?id=9dfd63db8152d602bfa95049a98803d3a06a30879dfcd935c88a530be20311fe","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Quest Diagnostics is expected to unveil its second-quarter results later this month, and analysts expect a single-digit growth in earnings.","category":"company","datetime":1782917204,"headline":"Quest Diagnostics's Q2 2026 Earnings: What to Expect"}, {"id":140773035,"url":"https://finnhub.io/api/news?id=1a9df6d3e66681b87e33417a87fd52ba6bc6e255861fda7aeefb02e7c54e5838","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Here is how Coya Therapeutics, Inc. (COYA) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.","category":"company","datetime":1782826803,"headline":"Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year?"}, {"id":140764106,"url":"https://finnhub.io/api/news?id=f4fbe12de44dd4368caac0162ec6b1a256f57d5dae0fc7960291663304ece869","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Hematologic Malignancies Testing Market size & share revenue was valued at approximately USD 3.28 Billion in 2025 and is expected to reach USD 3.72 Billion in 2026 and is expected to reach around USD 12.47 Billion by 2035, at a CAGR of 14.4% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Abbott Laborato","category":"company","datetime":1782754200,"headline":"Global Hematologic Malignancies Testing Market Size/Share Worth USD 12.47 Billion by 2035 at a 14.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)"}, {"id":140762661,"url":"https://finnhub.io/api/news?id=436a621c27ef4c5a4c8af1390e6ab512fb77305db81ffffa5d81207c83cb97fb","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"ABT's Medical Devices unit builds on strong growth with new diabetes, heart rhythm and electrophysiology advances ahead of Q2 2026.","category":"company","datetime":1782739200,"headline":"How Abbott's Largest Segment Is Preparing for the Next Growth Phase"}, {"id":140734708,"url":"https://finnhub.io/api/news?id=50937ef665125a5be1abc99b47e86bdc8fdd6ca126ac9b39982f3129f5910fda","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Quest Diagnostics (NYSE:DGX) received New York State approval for its Haystack MRD liquid biopsy test, enabling nationwide use for detecting residual or recurrent cancer. The approval follows published research indicating the test’s high sensitivity for minimal residual disease monitoring. Quest Diagnostics also entered a national partnership with Attunio Health to support an AI powered precision psychiatry platform. The partnership is intended to provide scalable laboratory infrastructure...","category":"company","datetime":1782472066,"headline":"Quest Diagnostics (DGX) Wins Nationwide Haystack MRD Access And Expands Into Psychiatry"}, {"id":140727543,"url":"https://finnhub.io/api/news?id=182b2260ba9344f85327967d71459609737e7d419a96acbfa7cca68fadeda24b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Just days after publicly launching its AI-powered precision psychiatry platform and gaining early media attention, Attunio Health announced a major expansion of its clinical infrastructure by selecting Quest Diagnostics as its national laboratory backbone and integrating Getlabs for at-home blood collection.","category":"company","datetime":1782406380,"headline":"Days After Launch, Attunio Health Expands Precision Psychiatry Infrastructure with Quest Diagnostics and Getlabs"}, {"id":140725943,"url":"https://finnhub.io/api/news?id=1cda39d77b9b3a359e1e145120f4ed6ac13bbd5d0df48bd64b01106b20f0d053","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Quest Diagnostics gains NYSDOH approval for Haystack MRD, expanding the cancer test to all 50 states and strengthening its oncology reach.","category":"company","datetime":1782397560,"headline":"DGX's Stock Rises on Haystack MRD Test's Approval From NYSDOH"}, {"id":140724703,"url":"https://finnhub.io/api/news?id=351b3eb19e715a16d21f59dd642061c9d64d6f75ffe01be0818f08d68b71cae8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Axtria Inc., a global leader in AI-first data & analytics solutions and platforms for the life sciences industry, hosted Axtria Ignite 2026 on June 10 and 11 at the Princeton Marriott at Forrestal under the theme \"Industrializing Intelligence: The Agentic Enterprise.\" More than 450 executives from over 100 leading life sciences, MedTech, and biotech organizations gathered to work through the harder question of 2026: what must be true before an enterprise can trust AI to run at machine speed.","category":"company","datetime":1782389700,"headline":"Axtria Ignite 2026: 450+ Life Sciences Leaders Convene With a Contrarian Message -- Fix the Foundation Before You Scale AI"}, {"id":140713099,"url":"https://finnhub.io/api/news?id=53dc744169136354e0769d3a58cf2b9dffb00df921da0fa90d1ef76305498a44","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Quest Diagnostics® (NYSE: DGX), a leading provider of diagnostic information services, today announced that the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) has approved the company's Haystack MRD® test, a circulating tumor DNA (ctDNA) liquid biopsy test, for use in identifying residual or recurring disease in patients with a range of solid tumor cancers.","category":"company","datetime":1782305520,"headline":"Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing"}, {"id":140717728,"url":"https://finnhub.io/api/news?id=18a5ba95dece6d3530402100f606cc8aa177cbabfe20db44473b936f9d8747c5","image":"","source":"Benzinga","related":"DGX","summary":"Quest Diagnostics® (NYSE:DGX), a leading provider of diagnostic information services, today announced that the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) has","category":"company","datetime":1782291347,"headline":"Quest Diagnostics Receives New York's Department of Health's Clinical Laboratory Evaluation Program Approval For Its Haystack Minimal Residual Disease Liquid Biopsy Test To Trace Residual Or Recurring Disease In Solid Tumor Cancers Patients"}, {"id":140701756,"url":"https://finnhub.io/api/news?id=2a5cee0556e50131a61755e46c92560b9e7e0316fe605a444b74909a75e5dd85","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"DGX gains from Advanced Diagnostics, physician and consumer testing growth, plus AI-driven efficiency efforts, even as debt and policy risks linger.","category":"company","datetime":1782219540,"headline":"Is it Apt to Hold Quest Diagnostics Stock in Your Portfolio Now?"}
data_source finnhub_news_keyword_model
article_count 4
negative_hits 0
positive_hits 1
recomputed_at_score true
sentiment_score_raw 0.6
source_article_count 21
discarded_article_count 17
sentimentPoints 4

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 3.7 5/110 74% 3.7
資金流 7.6 20/110 38% 7.6
市場環境 8 15/110 53.33% 8
催化劑 2 20/110 10% 2
風險管理 7.2 10/110 72% 7.2
技術信號 17.4 30/110 58% 17.4
情緒分析 4 10/110 40% 4

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 5/50
ret_5d 0.0015
max_score 50
max_total 50
raw_total 5
vcp_bonus 0
vol_ratio 0.6906
ret_points 4
vol_points 0
range_ratio 1.1409
volat_points 0
day_range_pct 0.026
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 1
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Medium
reason risk management score >= 6.5/10

position

score 1.4

details

atrPct 2.3982
turnoverUsdM 129.9497
liquidityPoints 0.4
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.DGX
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 197.7

strength_details

ma_score 1.5
atr_score 2
rsi_score 1
macd_score 1.5
volume_score 1
market_adjustment 1
risk_reward_ratio 1
stop_loss_percent 4.8
take_profit_price 218.043
target_multiplier 1.6
technical_strength 1.38
take_profit_percent 5
positionPoints 1.4
stopLossPoints 2.4

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 4.7963
diversificationPoints 2

Calculation audit log

基本面分析總分: 3.7/5分
資金流分析總分: 7.6/20分
市場環境分析總分: 8/15分
催化劑分析: 2/20分
風險管理總分: 7.2/10分
技術信號分析總分: 17.4/30分
情緒分析: 4/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 92.86
atr
atr 4.98
rule ATR / current price; lower volatility scores higher
score 6
atr_pct 2.4
cci
rule Cursor_18.24 CCI bands
level 平衡
score 6
value 3.21
cmf
rule Cursor_18.24 CMF bands
level 平衡
score 4
value 0.007
kdj
d 35.31
j 51.56
k 40.73
rule Cursor_18.24 K/D cross
score 4
signal 金叉
mfi
rule Cursor_18.24 MFI bands
level 平衡
score 6
value 53.9
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 2
trend 資金流出
value -5234981
recentSlope -331618.1
previousSlope 245160
rsi
value 41.95
sar
rule Cursor_18.24 Parabolic SAR
score 4
trend 下降
value 213.2572
position SAR喺價上
distancePct 2.7
previousTrend 下降
ma50
value 200.143
macd
macd 1.968
trend 中性偏多
signal 2.6225
histogram -0.6545
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 2
value 207.6815
position <VWAP
consecutiveAbove 0
volume
rule Cursor_18.24 volume ratio
level 空升
ratio 0.72
score 2
avgVolume 872799
currentVolume 625781
derived
ma20 207.936
ma50 200.143
prevClose 210.68
avgVolume10 819168
avgVolume20 872799
changePercent -1.43
avgVolumeForScore 872799
ma_cross
ma20 207.936
ma50 200.143
rule Cursor_18.24 MA20/MA50 cross
cross 多頭
score 4
prevMa20 207.303
prevMa50 199.7724
spreadPct 3.89
isVolumeBreakout false
bollinger
lower 196.8158
upper 219.0562
position 中間
rsi_short
value 50.63
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 0.72

Raw calculation JSON

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.4,
      "details": {
        "atrPct": 2.3981508234614273,
        "turnoverUsdM": 129.94968246,
        "liquidityPoints": 0.4,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.DGX",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 197.7,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 1,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 4.8,
      "take_profit_price": 218.043,
      "target_multiplier": 1.6,
      "technical_strength": 1.38,
      "take_profit_percent": 5
    },
    "positionPoints": 1.4,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 4.7963016469228545,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 54.9,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 49.9,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 5
  },
  "market": {
    "ma20": 207.936,
    "ma50": 200.143,
    "close": 207.66,
    "prevClose": 210.68,
    "avgVolume20": 872799,
    "volumeRatio": 0.72,
    "changePercent": -1.43
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 5,
    "details": {
      "ret_5d": 0.0014950083677351955,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 5,
      "vcp_bonus": 0,
      "vol_ratio": 0.6906160331964861,
      "ret_points": 4,
      "vol_points": 0,
      "range_ratio": 1.1409046981357847,
      "volat_points": 0,
      "day_range_pct": 0.025955889434652733,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 54.9,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 3.7,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 74,
        "contribution": 3.7
      },
      {
        "raw": 7.6,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 38,
        "contribution": 7.6
      },
      {
        "raw": 8,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 53.33,
        "contribution": 8
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.2,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 72,
        "contribution": 7.2
      },
      {
        "raw": 17.4,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 58,
        "contribution": 17.4
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 49.9,
    "details": [
      "基本面分析總分: 3.7/5分",
      "資金流分析總分: 7.6/20分",
      "市場環境分析總分: 8/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.2/10分",
      "技術信號分析總分: 17.4/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 3.7,
      "資金流": 7.6,
      "市場環境": 8,
      "情緒分析": 4,
      "技術信號": 17.4,
      "風險管理": 7.2
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 4,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "良好",
        "items": {
          "pbPoints": 0.4,
          "pePoints": 0.4,
          "epsPoints": 0.4,
          "roePoints": 0.4,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 129.94968246,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 2.4,
          "obvPoints": 0.8,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.DGX",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 1.8,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 18.77
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 716.11750425,
                "ma50": 719.0110022000002,
                "name": "QQQ",
                "close": 696.059998,
                "points": 0.4
              },
              "spy": {
                "ma20": 744.7885068500001,
                "ma50": 744.54560184,
                "name": "SPY",
                "close": 742.090027,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.3981508234614273,
          "atrPoints": 3,
          "cciPoints": 2.4,
          "vixPoints": 1.8,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 4,
              "negativeHits": 0,
              "positiveHits": 1,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 140869905,
                "url": "https://finnhub.io/api/news?id=7c44cbdf232fd722d46c7c1836b6ff306d3c7cf5dce2f2dc1a99ca8db8c171f0",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) passes the \"Best Dividend\" screen with a sustainable 1.59% yield, low 35% payout ratio, and strong profitability. A solid choice for reliable dividend income and growth.",
                "category": "company",
                "datetime": 1783763431,
                "headline": "Quest Diagnostics (NYSE:DGX) Offers a Secure and Sustainable Dividend with Strong Profitability"
              },
              {
                "id": 140791609,
                "url": "https://finnhub.io/api/news?id=1163bcc6bf803bb433b2cba9b963d451d95a47f2b2b2a3bc11367cdfed6d0641",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.",
                "category": "company",
                "datetime": 1782998102,
                "headline": "Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?"
              },
              {
                "id": 140734708,
                "url": "https://finnhub.io/api/news?id=50937ef665125a5be1abc99b47e86bdc8fdd6ca126ac9b39982f3129f5910fda",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (NYSE:DGX) received New York State approval for its Haystack MRD liquid biopsy test, enabling nationwide use for detecting residual or recurrent cancer. The approval follows published research indicating the test’s high sensitivity for minimal residual disease monitoring. Quest Diagnostics also entered a national partnership with Attunio Health to support an AI powered precision psychiatry platform. The partnership is intended to provide scalable laboratory infrastructure...",
                "category": "company",
                "datetime": 1782472066,
                "headline": "Quest Diagnostics (DGX) Wins Nationwide Haystack MRD Access And Expands Into Psychiatry"
              },
              {
                "id": 140725943,
                "url": "https://finnhub.io/api/news?id=1cda39d77b9b3a359e1e145120f4ed6ac13bbd5d0df48bd64b01106b20f0d053",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics gains NYSDOH approval for Haystack MRD, expanding the cancer test to all 50 states and strengthening its oncology reach.",
                "category": "company",
                "datetime": 1782397560,
                "headline": "DGX's Stock Rises on Haystack MRD Test's Approval From NYSDOH"
              }
            ],
            "raw_source": [
              {
                "id": 140940379,
                "url": "https://finnhub.io/api/news?id=313b6b852fad87101bd818b159b0149e5266b64044b5717f092ff2ac4d12ad63",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "DGX",
                "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read here for an analysis.",
                "category": "company",
                "datetime": 1784329960,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of July 19"
              },
              {
                "id": 140898445,
                "url": "https://finnhub.io/api/news?id=8cce6b82d94a14e6f1c6129d038c9d068492f45c6095479b1ffc1aafdad7bbfa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "DGX's Q2 results may reflect growth across physician, hospital and consumer channels as AI tools and advanced diagnostics gain traction.",
                "category": "company",
                "datetime": 1784037480,
                "headline": "Quest Diagnostics to Report Q2 Earnings: Key Customer Channels in Focus"
              },
              {
                "id": 140898225,
                "url": "https://finnhub.io/api/news?id=b650bd0404d07d15723345af5bfd6859bfe7fe9df9d504ab0885e15a63cbfe95",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "ABT heads into Q2 earnings results with growth expected across Diagnostics, Devices and EPD, while Nutrition remains a drag. Here's what could shape the results.",
                "category": "company",
                "datetime": 1784036040,
                "headline": "Abbott's Q2 Earnings on Deck: How Should You Play the Stock Now?"
              },
              {
                "id": 140886479,
                "url": "https://finnhub.io/api/news?id=8d5d12187252ef0e8147e50d9c59ae99b9b436fe3ec1128d445997fa97f1f15a",
                "image": "",
                "source": "Benzinga",
                "related": "DGX",
                "summary": "Baird  analyst Eric Coldwell   maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $232 to $236.",
                "category": "company",
                "datetime": 1783929439,
                "headline": "Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $236"
              },
              {
                "id": 140869905,
                "url": "https://finnhub.io/api/news?id=7c44cbdf232fd722d46c7c1836b6ff306d3c7cf5dce2f2dc1a99ca8db8c171f0",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) passes the \"Best Dividend\" screen with a sustainable 1.59% yield, low 35% payout ratio, and strong profitability. A solid choice for reliable dividend income and growth.",
                "category": "company",
                "datetime": 1783763431,
                "headline": "Quest Diagnostics (NYSE:DGX) Offers a Secure and Sustainable Dividend with Strong Profitability"
              },
              {
                "id": 140861842,
                "url": "https://finnhub.io/api/news?id=dea4a96367e9b1a7e12508fa236e7172cb3413edda8b934757bfbaf6b5228b7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Nearly one in five workers in the general U.S. workforce (19.1%) tested positive for drug use based on an analysis of hair specimens collected in 2025, an increase of nearly 46% compared to 13.1% in 2021, finds the 2026 Quest Diagnostics Drug Testing Index™. For more information, visit www.QuestDiagnostics.com/DTI.",
                "category": "company",
                "datetime": 1783689840,
                "headline": "One in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use Patterns"
              },
              {
                "id": 140840711,
                "url": "https://finnhub.io/api/news?id=70f8fddaf6c1d9f28cfb731d0d184f3c03704f72b9b47c49b3aad0e44c40e3a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced it is integrating its Haystack MRD® ctDNA test and Comprehensive Genomic Profiling services for solid tumor cancers within OncoEMR®, an electronic health record (EHR) from Flatiron Health, via a pilot program with American Oncology Network (AON) and other community oncology providers. Flatiron Health is a leading healthtech company dedicated to expanding the possibilities of point-of-care soluti",
                "category": "company",
                "datetime": 1783515120,
                "headline": "Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI"
              },
              {
                "id": 140821261,
                "url": "https://finnhub.io/api/news?id=b7403286549b8549769139c3ef0d824ea7877567456fd904a8591fea24374fc6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Zacks highlights PDF Solutions, LifeStance Health and Paychex among stocks and portfolios that outperformed as markets weighed softer jobs data and earnings.",
                "category": "company",
                "datetime": 1783343700,
                "headline": "Beat the Market the Zacks Way: PDF Solutions, LifeStance Health, Paychex in Focus"
              },
              {
                "id": 140795133,
                "url": "https://finnhub.io/api/news?id=52987caaba1d0a4214a3d3520e4a63c4492060fd2ae8de73a16ba58c60747c14",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "DGX",
                "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Explore this week’s dividend updates.",
                "category": "company",
                "datetime": 1783015043,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of July 5"
              },
              {
                "id": 140791609,
                "url": "https://finnhub.io/api/news?id=1163bcc6bf803bb433b2cba9b963d451d95a47f2b2b2a3bc11367cdfed6d0641",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.",
                "category": "company",
                "datetime": 1782998102,
                "headline": "Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?"
              },
              {
                "id": 140784902,
                "url": "https://finnhub.io/api/news?id=9dfd63db8152d602bfa95049a98803d3a06a30879dfcd935c88a530be20311fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics is expected to unveil its second-quarter results later this month, and analysts expect a single-digit growth in earnings.",
                "category": "company",
                "datetime": 1782917204,
                "headline": "Quest Diagnostics's Q2 2026 Earnings: What to Expect"
              },
              {
                "id": 140773035,
                "url": "https://finnhub.io/api/news?id=1a9df6d3e66681b87e33417a87fd52ba6bc6e255861fda7aeefb02e7c54e5838",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Here is how Coya Therapeutics, Inc. (COYA) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.",
                "category": "company",
                "datetime": 1782826803,
                "headline": "Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year?"
              },
              {
                "id": 140764106,
                "url": "https://finnhub.io/api/news?id=f4fbe12de44dd4368caac0162ec6b1a256f57d5dae0fc7960291663304ece869",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Hematologic Malignancies Testing Market size & share revenue was valued at approximately USD 3.28 Billion in 2025 and is expected to reach USD 3.72 Billion in 2026 and is expected to reach around USD 12.47 Billion by 2035, at a CAGR of 14.4% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Abbott Laborato",
                "category": "company",
                "datetime": 1782754200,
                "headline": "Global Hematologic Malignancies Testing Market Size/Share Worth USD 12.47 Billion by 2035 at a 14.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)"
              },
              {
                "id": 140762661,
                "url": "https://finnhub.io/api/news?id=436a621c27ef4c5a4c8af1390e6ab512fb77305db81ffffa5d81207c83cb97fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "ABT's Medical Devices unit builds on strong growth with new diabetes, heart rhythm and electrophysiology advances ahead of Q2 2026.",
                "category": "company",
                "datetime": 1782739200,
                "headline": "How Abbott's Largest Segment Is Preparing for the Next Growth Phase"
              },
              {
                "id": 140734708,
                "url": "https://finnhub.io/api/news?id=50937ef665125a5be1abc99b47e86bdc8fdd6ca126ac9b39982f3129f5910fda",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (NYSE:DGX) received New York State approval for its Haystack MRD liquid biopsy test, enabling nationwide use for detecting residual or recurrent cancer. The approval follows published research indicating the test’s high sensitivity for minimal residual disease monitoring. Quest Diagnostics also entered a national partnership with Attunio Health to support an AI powered precision psychiatry platform. The partnership is intended to provide scalable laboratory infrastructure...",
                "category": "company",
                "datetime": 1782472066,
                "headline": "Quest Diagnostics (DGX) Wins Nationwide Haystack MRD Access And Expands Into Psychiatry"
              },
              {
                "id": 140727543,
                "url": "https://finnhub.io/api/news?id=182b2260ba9344f85327967d71459609737e7d419a96acbfa7cca68fadeda24b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Just days after publicly launching its AI-powered precision psychiatry platform and gaining early media attention, Attunio Health announced a major expansion of its clinical infrastructure by selecting Quest Diagnostics as its national laboratory backbone and integrating Getlabs for at-home blood collection.",
                "category": "company",
                "datetime": 1782406380,
                "headline": "Days After Launch, Attunio Health Expands Precision Psychiatry Infrastructure with Quest Diagnostics and Getlabs"
              },
              {
                "id": 140725943,
                "url": "https://finnhub.io/api/news?id=1cda39d77b9b3a359e1e145120f4ed6ac13bbd5d0df48bd64b01106b20f0d053",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics gains NYSDOH approval for Haystack MRD, expanding the cancer test to all 50 states and strengthening its oncology reach.",
                "category": "company",
                "datetime": 1782397560,
                "headline": "DGX's Stock Rises on Haystack MRD Test's Approval From NYSDOH"
              },
              {
                "id": 140724703,
                "url": "https://finnhub.io/api/news?id=351b3eb19e715a16d21f59dd642061c9d64d6f75ffe01be0818f08d68b71cae8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Axtria Inc., a global leader in AI-first data & analytics solutions and platforms for the life sciences industry, hosted Axtria Ignite 2026 on June 10 and 11 at the Princeton Marriott at Forrestal under the theme \"Industrializing Intelligence: The Agentic Enterprise.\" More than 450 executives from over 100 leading life sciences, MedTech, and biotech organizations gathered to work through the harder question of 2026: what must be true before an enterprise can trust AI to run at machine speed.",
                "category": "company",
                "datetime": 1782389700,
                "headline": "Axtria Ignite 2026: 450+ Life Sciences Leaders Convene With a Contrarian Message -- Fix the Foundation Before You Scale AI"
              },
              {
                "id": 140713099,
                "url": "https://finnhub.io/api/news?id=53dc744169136354e0769d3a58cf2b9dffb00df921da0fa90d1ef76305498a44",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics® (NYSE: DGX), a leading provider of diagnostic information services, today announced that the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) has approved the company's Haystack MRD® test, a circulating tumor DNA (ctDNA) liquid biopsy test, for use in identifying residual or recurring disease in patients with a range of solid tumor cancers.",
                "category": "company",
                "datetime": 1782305520,
                "headline": "Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing"
              },
              {
                "id": 140717728,
                "url": "https://finnhub.io/api/news?id=18a5ba95dece6d3530402100f606cc8aa177cbabfe20db44473b936f9d8747c5",
                "image": "",
                "source": "Benzinga",
                "related": "DGX",
                "summary": "Quest Diagnostics® (NYSE:DGX), a leading provider of diagnostic information services, today announced that the New York State Department of Health&#39;s (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) has",
                "category": "company",
                "datetime": 1782291347,
                "headline": "Quest Diagnostics Receives New York's Department of Health's Clinical Laboratory Evaluation Program Approval For Its Haystack Minimal Residual Disease Liquid Biopsy Test To Trace Residual Or Recurring Disease In Solid Tumor Cancers Patients"
              },
              {
                "id": 140701756,
                "url": "https://finnhub.io/api/news?id=2a5cee0556e50131a61755e46c92560b9e7e0316fe605a444b74909a75e5dd85",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "DGX gains from Advanced Diagnostics, physician and consumer testing growth, plus AI-driven efficiency efforts, even as debt and policy risks linger.",
                "category": "company",
                "datetime": 1782219540,
                "headline": "Is it Apt to Hold Quest Diagnostics Stock in Your Portfolio Now?"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 4,
            "negative_hits": 0,
            "positive_hits": 1,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 21,
            "discarded_article_count": 17
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 17.4,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 1.5,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.5,
            "vcp_reason": "跌縮量(近10日5日);站上MA50;升放量(近10日2日);Ready=N;Confirm=N",
            "vcp_metrics": {
              "up_days": 2,
              "vol_ref": 893080,
              "down_days": 7,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 831180,
              "avg_vol_20": 906120,
              "avg_vol_30": 893080,
              "range_pct_10": 0.0876432630261003,
              "range_pct_20": 0.12698642010979475,
              "range_pct_30": 0.12698642010979475,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.9306892999507324,
              "dist_to_20d_high": 0.05264598540145982,
              "down_shrink_days": 5,
              "breakout_level_20d": 219.2,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.6901782328403491
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.4,
            "details": {
              "atrPct": 2.3981508234614273,
              "turnoverUsdM": 129.94968246,
              "liquidityPoints": 0.4,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.DGX",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 197.7,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 1,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 4.8,
            "take_profit_price": 218.043,
            "target_multiplier": 1.6,
            "technical_strength": 1.38,
            "take_profit_percent": 5
          },
          "positionPoints": 1.4,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 4.7963016469228545,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 4.98,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.4
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "平衡",
      "score": 6,
      "value": 3.21
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.007
    },
    "kdj": {
      "d": 35.31,
      "j": 51.56,
      "k": 40.73,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 53.9
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": -5234981,
      "recentSlope": -331618.1,
      "previousSlope": 245160
    },
    "rsi": 41.95,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 213.2572,
      "position": "SAR喺價上",
      "distancePct": 2.7,
      "previousTrend": "下降"
    },
    "ma50": 200.143,
    "macd": {
      "macd": 1.967975733311988,
      "trend": "中性偏多",
      "signal": 2.6225113061001917,
      "histogram": -0.6545355727882036
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 207.6815,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.72,
      "score": 2,
      "avgVolume": 872799,
      "currentVolume": 625781
    },
    "derived": {
      "ma20": 207.936,
      "ma50": 200.143,
      "prevClose": 210.68,
      "avgVolume10": 819168,
      "avgVolume20": 872799,
      "changePercent": -1.43,
      "avgVolumeForScore": 872799
    },
    "ma_cross": {
      "ma20": 207.936,
      "ma50": 200.143,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 207.303,
      "prevMa50": 199.7724,
      "spreadPct": 3.89,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 196.8158,
      "upper": 219.0562,
      "position": "中間"
    },
    "rsi_short": 50.63,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.72
    }
  }
}

Raw metrics JSON

{
  "close": 207.66,
  "volume": 625781,
  "changePercent": -1.43
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.